Catalyst Pharmaceuticals (CPRX) Revenue & Revenue Breakdown
Catalyst Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$491.73M
Latest Revenue (Q)
$141.42M
Main Segment (Y)
Product Revenue Net
Main Geography (Y)
CANADA
Catalyst Pharmaceuticals Revenue by Period
Catalyst Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $491.73M | 23.49% |
| 2023-12-31 | $398.20M | 85.90% |
| 2022-12-31 | $214.20M | 52.10% |
| 2021-12-31 | $140.83M | 18.27% |
| 2020-12-31 | $119.07M | 16.39% |
| 2019-12-31 | $102.31M | 20361.27% |
| 2018-12-31 | $500.00K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | -100.00% |
| 2010-12-31 | $488.96K | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2007-12-31 | - | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | - |
Catalyst Pharmaceuticals generated $491.73M in revenue during NA 2024, up 23.49% compared to the previous quarter, and up 480.65% compared to the same period a year ago.
Catalyst Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $141.42M | -0.28% |
| 2024-12-31 | $141.82M | 10.20% |
| 2024-09-30 | $128.69M | 4.88% |
| 2024-06-30 | $122.71M | 24.57% |
| 2024-03-31 | $98.51M | -10.91% |
| 2023-12-31 | $110.57M | 7.67% |
| 2023-09-30 | $102.69M | 3.12% |
| 2023-06-30 | $99.58M | 16.65% |
| 2023-03-31 | $85.37M | 40.50% |
| 2022-12-31 | $60.76M | 6.14% |
| 2022-09-30 | $57.24M | 7.78% |
| 2022-06-30 | $53.11M | 23.26% |
| 2022-03-31 | $43.09M | 12.48% |
| 2021-12-31 | $38.31M | 6.55% |
| 2021-09-30 | $35.95M | -1.13% |
| 2021-06-30 | $36.37M | 20.39% |
| 2021-03-31 | $30.20M | -2.61% |
| 2020-12-31 | $31.01M | 5.79% |
| 2020-09-30 | $29.32M | -0.97% |
| 2020-06-30 | $29.60M | 1.61% |
| 2020-03-31 | $29.14M | -3.27% |
| 2019-12-31 | $30.12M | -2.51% |
| 2019-09-30 | $30.90M | 7.14% |
| 2019-06-30 | $28.84M | 131.66% |
| 2019-03-31 | $12.45M | 2389.69% |
| 2018-12-31 | $500.00K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | -100.00% |
| 2010-12-31 | $488.96K | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Catalyst Pharmaceuticals generated $141.42M in revenue during Q1 2025, up -0.28% compared to the previous quarter, and up 127.90% compared to the same period a year ago.
Catalyst Pharmaceuticals Revenue Breakdown
Catalyst Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 19 |
|---|---|---|---|---|---|
| Product Revenue Net | $489.33M | $396.50M | $213.94M | $138.00M | - |
| License And Other Revenue | $2.41M | $1.70M | $265.00K | $2.84M | - |
| Collaborative Arrangement Products Agreement | - | - | - | - | - |
| Product | - | - | - | - | $102.31M |
Catalyst Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product Revenue Net (99.51%), and License And Other Revenue (0.49%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License And Other Revenue | $23.00K | $21.00K | $68.00K | $2.27M | $68.00K | $1.46M | $71.00K | $105.00K | $62.00K | $74.00K | $71.00K | $64.00K | $56.00K | - | - | - |
| Product Revenue Net | $146.54M | $141.40M | $264.46M | $126.42M | $98.44M | $109.10M | $102.62M | $99.48M | $85.30M | $60.68M | $57.17M | $53.05M | $43.03M | $38.27M | - | - |
| Product Revenue, Net | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $35.89M | $33.64M |
Catalyst Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product Revenue Net (99.98%), and License And Other Revenue (0.02%).
Catalyst Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 |
|---|---|
| CANADA | $33.00K |
Catalyst Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 20: CANADA (100.00%).
Quarterly Revenue by Country
| Country | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|
| Product Revenue Net | $99.48M | $85.30M | $60.68M | $57.17M | $53.05M | $43.03M | $38.27M | - | - |
| License And Other Revenue | $105.00K | $62.00K | $74.00K | $71.00K | $64.00K | $56.00K | - | - | - |
| Product Revenue, Net | - | - | - | - | - | - | - | $35.89M | $33.64M |
Catalyst Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 23: Product Revenue Net (99.89%), and License And Other Revenue (0.11%).
Catalyst Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FOLD | Amicus Therapeutics | $528.29M | $154.69M |
| CPRX | Catalyst Pharmaceuticals | $491.73M | $141.42M |
| ARQT | Arcutis Biotherapeutics | $196.54M | $65.85M |
| ADPT | Adaptive Bio | $178.96M | $58.88M |
| RXRX | Recursion Pharmaceuticals | $58.84M | $19.22M |
| AGIO | Agios Pharmaceuticals | $36.50M | $12.46M |
| IBRX | ImmunityBio | $14.74M | $26.43M |
| IDYA | IDEAYA Biosciences | $7.00M | - |
| NTLA | Intellia Therapeutics | - | $16.63M |
| IRON | Disc Medicine | - | - |
| BEAM | Beam Therapeutics | - | - |